Detalhe da pesquisa
1.
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
N Engl J Med
; 387(20): 1855-1864, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342163
2.
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Arterioscler Thromb Vasc Biol
; 44(5): 1156-1164, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38545781
3.
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Circulation
; 147(16): 1192-1203, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779348
4.
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation
; 146(15): 1109-1119, 2022 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031810
5.
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
Cardiovasc Drugs Ther
; 2022 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435949
6.
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Cardiovasc Diabetol
; 20(1): 94, 2021 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941192
7.
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics.
Am Heart J
; 220: 203-212, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841795
8.
PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults.
J Lipid Res
; 60(11): 1946-1952, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511398
9.
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
J Am Coll Cardiol
; 83(6): 652-664, 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38325990
10.
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
J Am Coll Cardiol
; 83(9): 873-886, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418000
11.
Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation.
J Clin Lipidol
; 17(4): 529-537, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331900
12.
Heterogeneity of Lipoprotein(a) Levels Among Hispanic or Latino Individuals Residing in the US.
JAMA Cardiol
; 8(7): 691-696, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37223894
13.
Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.
Eur Heart J Open
; 3(4): oead077, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641636
14.
Ancestral diversity in lipoprotein(a) studies helps address evidence gaps.
Open Heart
; 10(2)2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37648373
15.
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.
AIDS
; 36(5): 675-682, 2022 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025817
16.
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease.
J Am Heart Assoc
; 11(11): e025397, 2022 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35621195
17.
Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.
J Diabetes Complications
; 35(3): 107767, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33168394
18.
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.
J Am Heart Assoc
; 10(1): e016839, 2021 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325247
19.
Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease.
Am J Cardiol
; 137: 7-11, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32991855
20.
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
J Am Heart Assoc
; 9(5): e014129, 2020 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32114889